novavax covid vaccine

Order byBest matchMost fresh

Novavax Soars

Healthy Returns: Novavax scores narrower Covid vaccine approval after delay

Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's Covid-19 vaccine after more than a month of delay b

· 18h · on MSN

Infectious Disease Advisor · 1h

FDA Approves Novavax’s COVID-19 Vaccine Nuvaxovid

· 2d · on MSN

Novavax Soars After Covid Vaccine Secures Full FDA Approval

WA vaccine scientists push back against FDA changes around COVID shots

Seattle vaccine experts were surprised and confused by the country’s apparent new direction around updated COVID-19 shots, which top officials at the Food and Drug Administration revealed Tuesday and ...

· 2h

· 14h

F.D.A. Poised to Restrict Access to Covid Vaccines

· 23h

Annual COVID-19 Shots For Healthy Younger Adults, Children Will No Longer Be Routinely Approved

New Trump vaccine policy limits access to COVID shots

The Trump administration said Tuesday it will limit approval for seasonal COVID-19 shots to seniors and others at high risk pending more data on everyone else — raising questions about whether some p...

· 19h

· 22h

FDA sets new COVID booster guidelines for healthy adults under 65

· 17h

FDA may limit future Covid-19 shots to older people and those at risk of serious infection

FDA’s new approach raises questions about fall COVID vaccine availability

Health experts say there are legitimate questions about how much everyone still benefits from yearly COVID vaccination or whether they should be recommended only for people at increased risk.

1don MSN

RFK Jr. pledged not to upend US vaccine system, but big changes are underway

WASHINGTON — Robert F. Kennedy Jr. clinched the political support needed to become the nation’s top health official by pledging to work within the decades-old federal system for approval and use of vaccines. Yet his regulators are promising big changes that cloud the outlook for what shots might even be available.

Novavax (NasdaqGS:NVAX) Reports Q1 2025 Financial Turnaround

Novavax (NasdaqGS:NVAX) recently reported a significant financial turnaround for Q1 2025, demonstrating substantial revenue growth and net income improvements. The amending of its collaboration agreement with Takeda offers increased flexibility in vaccine development,